Home › Kidney Cancer › Connecticut › New Haven
Kidney Cancer clinical trials in New Haven, CT
4 studies for Kidney Cancer are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- NEO-811 Connecticut Site, New Haven
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RecruitingPhase 1
- Yale - New Haven Hospital, New Haven
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 3
- Research Site, New Haven
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- Xencor Investigative Site, New Haven
About Kidney Cancer
Kidney cancer symptoms are hard to detect at first but they do exist. Read more about the top 5 symptoms and the treatment options available
More about Kidney Cancer on MedlinePlus
Kidney Cancer trials in other cities
- New York City, NY15 studies
- Boston, MA12 studies
- Nashville, TN12 studies
- Houston, TX10 studies
- San Diego, CA9 studies
- Dallas, TX9 studies
- St. Louis, MO9 studies
- Washington, DC9 studies
- Seattle, WA8 studies
- Edison, NJ8 studies
- Miami, FL8 studies
- Los Angeles, CA7 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer38 studies
- Cancer (all types)33 studies
- Metastatic Cancer23 studies
- Lung Cancer22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Ovarian Cancer21 studies
- Colorectal Cancer20 studies
- Prostate Cancer20 studies
- Acute Myeloid Leukemia17 studies
- Alcohol Use Disorder (AUD)17 studies
- Opioid Overdose17 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.